Figure 1.
Clinical outcomes. (A) Cumulative incidence of complete response (CR) adjusted for competing risks, over the 6-month follow-up period after VST infusion. (B) Cumulative incidence of disease relapse and non-relapse mortality in the first 12 months after transplant. (C) Overall survival in the first 12 months after transplant. N = 30 for all.

Clinical outcomes. (A) Cumulative incidence of complete response (CR) adjusted for competing risks, over the 6-month follow-up period after VST infusion. (B) Cumulative incidence of disease relapse and non-relapse mortality in the first 12 months after transplant. (C) Overall survival in the first 12 months after transplant. N = 30 for all.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal